Á lódáil...
Exploring and comparing adverse events between PARP inhibitors
Ovarian cancer remains one of the most challenging malignancies to treat. Targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of the most exciting new treatments for ovarian cancer, particularly in women with BRCA1 or BRCA2 mutations or those without a funct...
Na minha lista:
| Foilsithe in: | Lancet Oncol |
|---|---|
| Main Authors: | , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
2019
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7292736/ https://ncbi.nlm.nih.gov/pubmed/30614472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30786-1 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|